Mizuho Maintains Buy on Cytokinetics, Raises Price Target to $103
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed has reaffirmed a Buy rating on Cytokinetics (NASDAQ:CYTK) and increased the price target from $80 to $103, indicating a positive outlook on the company's stock.
January 22, 2024 | 2:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Salim Syed maintains a Buy rating on Cytokinetics and raises the price target from $80 to $103, suggesting a strong confidence in the company's future performance.
The increase in price target by a reputable analyst typically signals a bullish outlook on the stock, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100